NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Mereo BioPharma Group plc (F: MAH0)

 
MAH0 Technical Analysis
1
As on 27th Aug 2024 MAH0 STOCK Price closed @ 4.45 and we RECOMMEND N/A for LONG-TERM with Stoploss of 0.00 & N/A for SHORT-TERM with Stoploss of 0.00 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

MAH0STOCK Price

Open 4.25 Change Price %
High 4.45 1 Day N/A N/A
Low 4.25 1 Week 0.00 0.00
Close 4.45 1 Month 0.00 0.00
Volume 1000 1 Year 0.00 0.00
52 Week High 0.00 | 52 Week Low 0.00
 
F Germany Most Active Stocks
IMU 0.10 %
IMU 0.10 %
IMU 0.10 %
IMU 0.10 %
IMU 0.10 %
ENB 47.60 -0.92%
TEF 3.84 -0.52%
TEF 3.84 -0.52%
WHL 5150.00 -0.44%
WDI 0.05 -37.50%
 
F Germany Top Gainers Stocks
0AI 11.30 14025.00%
0AI 11.30 14025.00%
SUE1 12.60 12500.00%
WPIA 6.22 871.88%
WPIA 6.22 871.88%
WPIA 6.22 871.88%
8S3B 1.73 620.83%
8S3B 1.73 620.83%
SY7P 0.07 600.00%
P9F1 1.75 326.83%
 
F Germany Top Losers Stocks
TINC 0.01 -99.92%
TINC 0.01 -99.92%
TINC 0.01 -99.92%
LDB 1.71 -92.57%
LDB 1.71 -92.57%
LDB 1.71 -92.57%
LDB 1.71 -92.57%
LDB 1.71 -92.57%
AETG 0.25 -91.61%
AETG 0.25 -91.61%
 
 
MAH0
Daily Charts
MAH0
Intraday Charts
Whats New @
Bazaartrend
MAH0
Free Analysis
 
MAH0 Important Levels Intraday
SUPPORT0.00
SUPPORT0.00
SUPPORT0.00
SUPPORT0.00
SUPPORT0.00
SUPPORT0.00
SUPPORT0.00
SUPPORT0.00
 
MAH0 Forecast September 2024
4th UP Forecast0
3rd UP Forecast0
2nd UP Forecast0
1st UP Forecast0
1st DOWN Forecast0
2nd DOWN Forecast0
3rd DOWN Forecast0
4th DOWN Forecast0
 
MAH0 Weekly Forecast
4th UP Forecast0.00
3rd UP Forecast0.00
2nd UP Forecast0.00
1st UP Forecast0.00
1st DOWN Forecast0.00
2nd DOWN Forecast0.00
3rd DOWN Forecast0.00
4th DOWN Forecast0.00
 
MAH0 Forecast2024
4th UP Forecast0
3rd UP Forecast0
2nd UP Forecast0
1st UP Forecast0
1st DOWN Forecast0
2nd DOWN Forecast0
3rd DOWN Forecast0
4th DOWN Forecast0
 
 
MAH0 Other Details
Segment EQ
Market Capital 203230416.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
MAH0 Address
MAH0
 
MAH0 Latest News
 
Your Comments and Response on Mereo BioPharma Group plc
 
MAH0 Business Profile
Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was founded in 2015 and is based in London, the United Kingdom. Address: 1 Cavendish Place, London, United Kingdom, W1G 0QF
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service